Immix Biopharma Reports 95% Complete Response Rate in NEXICART-2 AL Amyloidosis Trial
IMMX has more than doubled off its 52-week low of $1.87.
Summary
Immix Biopharma reported updated Phase 2 clinical trial results for NXC-201, showing a 95% complete response rate in AL Amyloidosis patients with no relapses observed to date, and plans for a Phase 3 trial in H1 2027.
Key Events · Product Development and Regulatory · IMMX
-
High Complete Response Rate Achieved
All four MRD-negative relapsed/refractory AL Amyloidosis patients announced at ASH 2025 have converted to complete response (CR). The overall CR rate for the first 20 patients in the NEXICART-2 trial is now 95% (19 out of 20 patients).
-
Durability and Rapid Response
No relapses have been observed to date for patients who have reached CR, and all CRs were achieved within one year of follow-up post-dosing. MRD-negativity was achieved within 30 days for all MRD-negative patients.
-
Advancing to Phase 3 Trial
The company plans to initiate a multi-center, randomized Phase 3 trial of NXC-201 in newly diagnosed AL Amyloidosis patients in the first half of 2027.
-
Next Clinical Update Expected
The next update from the ongoing NEXICART-2 clinical trial is expected in late September 2026.
Analysis · IMMX · Life Sciences
Immix Biopharma announced highly positive updated clinical trial results for its lead candidate NXC-201 in relapsed/refractory AL Amyloidosis. Achieving a 95% complete response (CR) rate with no observed relapses to date for CR patients, and rapid MRD-negativity, is a significant milestone for a Phase 2 trial, especially for a drug with Breakthrough Therapy Designation. This strong data substantially de-risks the development path and supports the company's plan to initiate a potentially registrational Phase 3 trial in the first half of 2027. The next update is expected in late September 2026.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMMX was trading at $9.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $486.4M. The 52-week trading range was $1.87 to $11.61. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.